Study by Erasmus MC marks first clinical development milestone for ISA104 immunotherapeutic treatment of chronic hepatitis B infection OEGSTGEEST, Netherlands, Aug. 31, 2023 /PRNewswire/ — ISA Pharmaceuticals B.V., a clinical-stage biotech company developing immunotherapies to treat…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.